Further study regarding the efficacy and safety of andaxanet is needed in these excluded populations.

This study is limited by its small sample size and by its population of only healthy volunteers without significant comorbidities or urgent indications for reversal of anticoagulation. Analysis of various biomarkers and measurements of anticoagulation was also very thorough.

This study is strengthened by its inclusion of older participants, who are often excluded from such trials, and as a result more closely approximates clinical practice. Furthermore, there were no adverse thrombotic or bleeding events in patients receiving andaxanet, thereby supporting its safety profile. Andaxanet was rapid in onset and offset of action, making it ideal for use when urgent reversal of anticoagulation is required. Study Rundown: The ANNEXA-A and ANNEXA-R trials demonstrated the efficacy of andaxanet alfa as a reversal agent for the direct factor Xa inhibitors apixaban and rivaroxaban. Original Date of Publication: December 2015

Annexa 4 trial